Cancer/Tumor Profiling Market – Analysis by Size, Growth

Description

Cancer/Tumor Profiling Market Synopsis

Cancer/Tumor Profiling Market Size Was Valued at USD 11.08 Billion in 2024, and is Projected to Reach USD 23.4 Billion by 2032, Growing at a CAGR of 9.8% From 2025-2032.

Cancer/tumor profiling allows elaborate examination of the tumor and analyzes the genetic features of the object. It has however gained importance in the recent past due to the fact that the various profiling techniques for cancer can reveal a lot about the cancer tumor. The information got from cancer profiling is used to develop the correct course of any treatment for any person with cancer. Cancer has become prevalent throughout the world and consequently; there is need to perform molecular profile to diagnose cancer. Notably, the rise in knowledge concerning various cancers, including breast, oral, pancreatic, and many others, contributes to the market expansion. Cancer profiling methods employed by oncologists allow them to make distinctions at the molecular level concerning cancer cells.

Cancer profiling is done through techniques for example next generation sequencing NGS, polymerase chain reaction PCR, in situ Hybridization ISH, immunohistochemistry IHC, microarray and others. The NGS segment which is the next-generation sequencing has the biggest market share and oncologist is seen to embrace the NGS technology in cancer profiling. Covers a high tumor sample or fresh frozen FNAs or CTCs; NGS is capable of deep sequencing of a given tumor biopsy. This helps in creating a detailed profile of the cancer through the identification of mutations hence increasing the utilization of NGS. However, fluorescence in situ hybridization has been recently applied in the diagnosis, because the sensitivity is higher than NGS. Currently, personalized medicine segment is expected to fuel the global market for FISH and NGS and the use of profiling panels in the routine diagnostic procedure is likely to rise in the years to come.

The techniques used in cancer profiling are genomics, proteomics, epigenetic, and metabolite profiling. Protomics is the second largest technique used in the cancer profiling market because the determination of the extent of proteins present in malignant tumour through proteomic profiling techniques is highly significant in the effective profiling of cancer. Protein Quantitative trait is important to aid in the right diagnosis as well as aid in therapy of the cancer patients. The global incidents of breast cancers and the growth in concern towards targeted treatment being provided for cancer patients should fuel the growth in the near future.

The current global market is mainly propelled by the rising need for cancer profiling method, especially among oncologists in the diagnosis and treatment of cancer and particularly in the ability to forecast fate to targeted therapy. Besides, growth in usage of cancer biomarkers for tumor, increased occurrence of cancer globally, and advanced usage of next generation sequencing technique for cancer have contributed to the market growth. Nevertheless, elevated cost on biomarkers and fewer specialized personnel or oncologists acquainted with tumor profiling act as a hindrance to the growth of the market.

Cancer/Tumor Profiling Market Trend Analysis

Cancer/Tumor Profiling Market Growth Driver- Rising Cancer Rates & Increasing Awareness

The escalating rate of cancer across the world is the most significant factor driving the development of the market. The essence of cancer profiling methods by oncologists in the developing economies is establishing the pattern for the growth of the market.

Cancer is unfortunatley on the rise globally attributed to issues such as increase in the world’s population, aging, and alteration of the populace’s lifestyles. This, along with an increasing culture of educated populations towards cancer, its diagnosis and treatment solutions is opening up a huge market for tumor profiling services

World health organization report of cancer in 2021 revealed that cancer was the leading cause of death with 13.6% million deaths globally. In the global context, trends in cancer incidence have been identified to be on the rise due to the growing population of aging people, changes in global diet, and other aspects of an individual’s environment. This results in increased need for adequate cancer diagnosis and treatment that will be suitable to different patients, which in turns creates the need for effective tumor profiling technologies.

Cancer/Tumor Profiling Market Opportunity- Government Investments in Healthcare Infrastructure

Market growth rate will be boosted by the federal governments’ increased funding of the same. Also, the increasing globalisation and liberalisation of the healthcare industry that has been stimulated by both public and private sectors particularly in the developing regions will foster market growth prospects. Also, the high return on investments guaranteed by the resurgent research activities and the growing personnel in the technologies exploring the field of cancer/tumor profiling will also benefit the market. Conversing, the boosting in the use of the cancer biomarkers for diagnosing cancer/tumor, global personal disposable income level increase in the number of technologically driven products to the hospitals, growing investment for the advanced medical products and instruments, rising need for Point of Care diagnostics, and increasing concern of personalized medicines among people have a positive impact on the market CAGR.

Cancer/Tumor Profiling Market Segment Analysis:

Cancer/Tumor Profiling Market Segmented based on Type, Technology, and Application.

By Type, Genomic segment is expected to dominate the market during the forecast period

Depending on Type, the market is divided into Genomic, Proteomic, Epigenetic, and Metabolomic. Of all the tumor profiling types, genomic profiling is predicted to be the largest and have the highest market share between yr. It involves identification of all the genes within the tumor, which gives information on the tumor’s genetic structure and abnormalities.

Genomic profiling has always maintained a prominence in the management of cancer, thanks to the increased use of new genomic technologies in oncology hence its leading position in the Cancer/Tumor Profiling Market.

By Technology, Next Generation Sequencing (NGS) segment held the largest share in 2024

Depending on the Technology the market can be segmented into Next Generation Sequencing, Polymerase Chain Reaction, Immunohistochemistry, In-Situ Hybridization, Mass Spectrometry and Microarray. The global market share distribution for tumor profiling technology demonstrates that Next Generation Sequencing (NGS) holds the largest market share. Its capacity to provide a holistic assessment of genes and ability to detect mutations makes it a popular tool among researchers and clinicians. Tumor biology can be elucidated more comprehensively by NGS and the therapeutic approaches for patients can be managed accordingly for better prognosis.

Cancer/Tumor Profiling Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

North America has been identified as having leadership research organizations and prominent pharmaceutical manufacturers as the key professionals in spearheading the development of tumor profiling technologies. These countries’ institutions are the engines that drive research and development in the field. Fine academic medical centers and clinical laboratories, having access to advanced detection instrumentation, define North America’s status as the world’s leading region in intricate tumor profiling. They have the superior means for in-depth examination of events and patterns. Substantial awareness towards and spending on healthcare organizations and facilities across the North American region drives the increased usage of innovative tumor profiling solutions. As a financial investment, it makes it possible for the region in question to be in a position to adopt modern technology and the best especially proven techniques.

In North America, a favourable regulatory setting for the medical field provides clear channels to new technologies which enables faster development and access to various methods of tumor profiling. This advantage enables them to be market pioneers in as far as the newest options available in the market are concerned.

Active Key Players in the Cancer/Tumor Profiling Market

Lucence Health Inc.

F. Hoffmann-La Roche Ltd

Caris Life Sciences

ACT Genomics Co., LTD

Thermo Fisher Scientific Inc.

Strand Life Sciences

IMB Dx, Inc.

Illumina, Inc.

Guardant Health

QIAGEN

Ribomed Biotechnologies Inc.

HTG Molecular Diagnostics, Inc.

NanoString

NeoGenomics Laboratories

Exact Sciences Corporation

Other Active Players